Fmcna - Trinity is a medicare approved dialysis facility center in Slidell, Louisiana and it has 8 dialysis stations. It is located in Saint Tammany county at 1400 Lindberg Dr, Slidell, LA, 70458. You can reach out to the office of Fmcna - Trinity at (985) 643-6753. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmcna - Trinity has the following ownership type - Profit. It was first certified by medicare in December, 2009. The medicare id for this facility is 192702 and it accepts patients under medicare ESRD program.
| Name | Fmcna - Trinity |
|---|---|
| Location | 1400 Lindberg Dr, Slidell, Louisiana |
| No. of Dialysis Stations | 8 |
| Medicare ID | 192702 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 1400 Lindberg Dr, Slidell, Louisiana, 70458 | |
| (985) 643-6753 | |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
| NPI Number | 1144289075 |
| Organization Name | Trinity Kidney Care Center |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 1400 Lindberg Dr Slidell, Louisiana, 70458 |
| Phone Number | (985) 661-9550 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
| NPI Number | 1396989984 |
| Organization Name | Fresenius Medical Care Trinity |
| Doing Business As | Bio-medical Applications Of Louisiana, Llc |
| Address | 1400 Lindberg Dr Slidell, Louisiana, 70458 |
| Phone Number | (985) 643-6753 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 13 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 23 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 22 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 167 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmcna - Trinity with elevated calcium levels.
| Patients with hypercalcemia | 22 |
| Hypercalcemia patient months | 167 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 23 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 18 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 32 |
| Patients with Serumphosphor greater than 7 mg/dL | 20 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 28 |
| Patient months included in arterial venous fistula and catheter summaries | 165 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 52 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 32 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 23 |
| Hospitalization Rate in facility | 348.4 (Worse than Expected) |
| Hospitalization Rate: Upper Confidence Limit | 657.8 |
| Hospitalization Rate: Lower Confidence Limit | 194.1 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Fmcna - Trinity were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 34.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 44.3 |
| Readmission Rate: Lower Confidence Limit | 25.4 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmcna - Trinity get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 2.94 (Worse than Expected) |
| SIR: Upper Confidence Limit | 6.51 |
| SIR: Lower Confidence Limit | 1.08 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmcna - Trinity's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 13 |
| Transfusion Rate in facility | (Not Available) |
| Transfusion Rate: Upper Confidence Limit | |
| Transfusion Rate: Lower Confidence Limit |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Fmcna - Trinity lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 122 |
| Mortality Rate in facility | 42.7 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 63.6 |
| Mortality Rate: Lower Confidence Limit | 27.4 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago
Davita - Slidell Kidney Care Location: 662 Robert Blvd, Slidell, Louisiana, 70458 Phone: (985) 649-5197 |
Davita - Fremaux Dialysis Location: 1566 Shortcut Hwy, Slidell, Louisiana, 70458 Phone: (985) 643-9237 |
News Archive
Faced with annual health insurance costs of $6.3 billion, New York City is putting its health care contract out to bid, Mayor Michael Bloomberg said Friday. Bloomberg said the bid has not gone out yet but current health-insurance provider EmblemHealth has already chosen not to seek a rate increase for the next fiscal year (Mathews, 8/2).
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
A clinical trial for a new treatment for type 1 diabetes which potentially eliminates the need for daily insulin injections will commence in New Zealand by Australian company Living Cell Technologies (LCT).
Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
› Verified 9 days ago